Photo Credit: iStock.com/bymandesigns

Modest medication reduction was sustained postoperatively in both surgical groups, highlighting comparable long-term benefits. 

Researchers conducted a retrospective study published in June 2025 issue of Clinical Ophthalmology to compare postoperative outcomes in individuals who underwent cataract surgery with OMNI canaloplasty and Hydrus Microstent implantation vs those who received cataract surgery with OMNI canaloplasty alone.  

They used records of adults diagnosed with mild to moderate primary open-angle glaucoma and documented preoperative mild to moderate visual field loss. The outcome data was collected on intraocular pressure (IOP), the average number of prescribed ocular hypotensive medications, glaucoma secondary surgical interventions (SSI), and visual field measures, including mean deviation and pattern standard deviation. Data were analyzed for up to 24 months postoperatively.  

The results showed that chart review identified 45 eyes in the [Hydrus/OMNI Group] and 35 eyes in the [OMNI Group]. In the [Hydrus/OMNI Group], the average number of glaucoma medications decreased from 2.9 preoperatively to 2.1 in 24 months postoperatively. In the [OMNI Group], the mean number of medications declined from 1.9 to 1.6 over the same period. Mean IOP remained stable postoperatively in both groups.  

Investigators concluded that both combined cataract surgeries led to a sustained reduction in glaucoma medications over 2 years, with no significant difference between the [Hydrus/OMNI Group] and [OMNI Group]. 

Source: dovepress.com/retrospective-study-of-2-year-clinical-outcomes-of-combination-ab-inte-peer-reviewed-fulltext-article-OPTH